BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lin OS, Keeffe EB, Sanders GD, Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther. 2004;19:1159-1172. [PMID: 15153169 DOI: 10.1111/j.1365-2036.2004.01963.x] [Cited by in Crossref: 121] [Cited by in F6Publishing: 97] [Article Influence: 6.7] [Reference Citation Analysis]
Number Citing Articles
1 Huang DQ, Nguyen MH. Cost-effectiveness of HCC surveillance among HCV patients after sustained virological response with direct-acting antivirals. Liver Int 2021;41:3036-7. [PMID: 34587343 DOI: 10.1111/liv.15072] [Reference Citation Analysis]
2 Farhang Zangneh H, Wong WWL, Sander B, Bell CM, Mumtaz K, Kowgier M, van der Meer AJ, Cleary SP, Janssen HLA, Chan KKW, Feld JJ. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis. Clin Gastroenterol Hepatol. 2018;pii:S1542-3565(18)31394-6. [PMID: 30580095 DOI: 10.1016/j.cgh.2018.12.018] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
3 Shoreibah MG, Bloomer JR, McGuire BM, Massoud OI. Surveillance for hepatocellular carcinoma: evidence, guidelines and utilization. Am J Med Sci. 2014;347:415-419. [PMID: 24759379 DOI: 10.1097/maj.0000000000000200] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
4 Hunyady B, Gervain J, Horváth G, Makara M, Pár A, Szalay F, Telegdy L, Tornai I. [Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline]. Orv Hetil 2014;155 Suppl:3-24. [PMID: 24631886 DOI: 10.1556/OH.2013.29893] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Hasani FA, Knoepfli M, Gemperli A, Kollar A, Banz V, Kettenbach J, Jüni P, Dufour J. Factors affecting screening for hepatocellular carcinoma. Annals of Hepatology 2014;13:204-10. [DOI: 10.1016/s1665-2681(19)30883-x] [Cited by in Crossref: 12] [Article Influence: 1.5] [Reference Citation Analysis]
6 Fukuda H, Sato D, Moriwaki K, Ishida H. Differences in healthcare expenditure estimates according to statistical approach: A nationwide claims database study on patients with hepatocellular carcinoma. PLoS One 2020;15:e0237316. [PMID: 32790706 DOI: 10.1371/journal.pone.0237316] [Reference Citation Analysis]
7 Choi HH, Rodgers SK, Fetzer DT, Wasnik AP, Millet JD, Morgan TA, Dawkins A, Gabriel H, Kamaya A. Ultrasound Liver Imaging Reporting and Data System (US LI-RADS): An Overview with Technical and Practical Applications. Acad Radiol 2020:S1076-6332(20)30354-8. [PMID: 32718745 DOI: 10.1016/j.acra.2020.06.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
8 Robotin MC, Kansil M, Howard K, George J, Tipper S, Dore GJ, Levy M, Penman AG. Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening. J Hepatol. 2009;50:990-998. [PMID: 19303657 DOI: 10.1016/j.jhep.2008.12.022] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
9 Sherman M. Screening for hepatocellular carcinoma. Hepatology Research 2007;37:S152-65. [DOI: 10.1111/j.1872-034x.2007.00180.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
10 Hassett M, Yopp AC, Singal AG, Palmer BF. Surveillance for Hepatocellular Carcinoma: How Can We Do Better? The American Journal of the Medical Sciences 2013;346:308-13. [DOI: 10.1097/maj.0b013e31828318ff] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
11 Chen Q, Ayer T, Chhatwal J. Optimal M -Switch Surveillance Policies for Liver Cancer in a Hepatitis C–Infected Population. Operations Research 2018;66:673-96. [DOI: 10.1287/opre.2017.1706] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
12 Hunyady B, Gerlei Z, Gervain J, Horváth G, Lengyel G, Pár A, Rókusz L, Szalay F, Telegdy L, Tornai I, Werling K, Makara M. [Hepatitis C: diagnosis, anti-viral therapy, after-care. Hungarian consensus guideline]. Orv Hetil 2015;156:343-51. [PMID: 25702254 DOI: 10.1556/OH.2015.30106] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
13 Makara M, Horváth G, Gervain J, Pár A, Szalay F, Telegdy L, Tornai I, Újhelyi E, Hunyady B. Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis. Orvosi Hetilap 2012;153:375-94. [DOI: 10.1556/oh.2012.29338] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
14 Sherman M. Hepatocellular carcinoma: screening and staging. Clin Liver Dis. 2011;15:323-324, vii-x. [PMID: 21689616 DOI: 10.1016/j.cld.2011.03.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
15 Hunyady B, Gerlei Z, Gervain J, Horváth G, Lengyel G, Pár A, Rókusz L, Szalay F, Telegdy L, Tornai I, Werling K, Makara M. [In Process Citation]. Orv Hetil 2015;156 Suppl 1:3-23. [PMID: 26039413 DOI: 10.1556/OH.2015.30107] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
16 Marrero JA. Screening tests for hepatocellular carcinoma. Clin Liver Dis. 2005;9:235-251, vi. [PMID: 15831271 DOI: 10.1016/j.cld.2004.12.006] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 2.8] [Reference Citation Analysis]
17 Singal AG, Parikh ND, Rich NE, John BV, Pillai A. Hepatocellular Carcinoma Surveillance and Staging. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 27-51. [DOI: 10.1007/978-3-030-21540-8_2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Shih ST, Crowley S, Sheu JC. Cost-effectiveness analysis of a two-stage screening intervention for hepatocellular carcinoma in Taiwan. J Formos Med Assoc. 2010;109:39-55. [PMID: 20123585 DOI: 10.1016/s0929-6646(10)60020-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
19 Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, Bonfrer J, Ecke TH, Grossman HB, Hayes P, Hoffmann RT, Lerner SP, Löhe F, Louhimo J, Sawczuk I, Taketa K, Diamandis EP; National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem 2010;56:e1-48. [PMID: 20207771 DOI: 10.1373/clinchem.2009.133124] [Cited by in Crossref: 146] [Cited by in F6Publishing: 119] [Article Influence: 12.2] [Reference Citation Analysis]
20 Marrero JA, Pelletier S. Hepatocellular Carcinoma. Clinics in Liver Disease 2006;10:339-51. [DOI: 10.1016/j.cld.2006.05.012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
21 West J, Card TR, Aithal GP, Fleming KM. Risk of hepatocellular carcinoma among individuals with different aetiologies of cirrhosis: a population-based cohort study. Aliment Pharmacol Ther 2017;45:983-90. [DOI: 10.1111/apt.13961] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
22 Uyei J, Taddei TH, Kaplan DE, Chapko M, Stevens ER, Braithwaite RS. Setting ambitious targets for surveillance and treatment rates among patients with hepatitis C related cirrhosis impacts the cost-effectiveness of hepatocellular cancer surveillance and substantially increases life expectancy: A modeling study. PLoS One 2019;14:e0221614. [PMID: 31449554 DOI: 10.1371/journal.pone.0221614] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
23 Nash KL, Woodall T, Brown AS, Davies SE, Alexander GJ. Hepatocellular carcinoma in patients with chronic hepatitis C virus infection without cirrhosis. World J Gastroenterol 2010; 16(32): 4061-4065 [PMID: 20731020 DOI: 10.3748/wjg.v16.i32.4061] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
24 Plaz Torres MC, Bodini G, Furnari M, Marabotto E, Zentilin P, Strazzabosco M, Giannini EG. Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? Cancers (Basel). 2020;12. [PMID: 32486355 DOI: 10.3390/cancers12061422] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
25 Pereira OC, Feld JJ. Editorial commentary: sustained virologic response for patients with hepatitis C-related cirrhosis: a major milestone, but not quite a cure. Clin Infect Dis 2013;57:237-9. [PMID: 23616493 DOI: 10.1093/cid/cit237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
26 Marrero JA, Welling T. Modern Diagnosis and Management of Hepatocellular Carcinoma. Clinics in Liver Disease 2009;13:233-47. [DOI: 10.1016/j.cld.2009.02.007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
27 Adeniji N, Dhanasekaran R. Current and Emerging Tools for Hepatocellular Carcinoma Surveillance. Hepatol Commun 2021. [PMID: 34533885 DOI: 10.1002/hep4.1823] [Reference Citation Analysis]
28 Stevens ER, Nucifora KA, Hagan H, Jordan AE, Uyei J, Khan B, Dombrowski K, des Jarlais D, Braithwaite RS. Cost-effectiveness of Direct Antiviral Agents for Hepatitis C Virus Infection and a Combined Intervention of Syringe Access and Medication-assisted Therapy for Opioid Use Disorders in an Injection Drug Use Population. Clin Infect Dis 2020;70:2652-62. [PMID: 31400755 DOI: 10.1093/cid/ciz726] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
29 Sherman M. Modern Approach to Hepatocellular Carcinoma. Curr Gastroenterol Rep 2011;13:49-55. [DOI: 10.1007/s11894-010-0163-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
30 Ott P. What is the Value of Country-Based Surveillance Programmes? In: Williams R, Taylor-robinson SD, editors. Clinical Dilemmas in Primary Liver Cancer. Oxford: Wiley-Blackwell; 2011. pp. 97-104. [DOI: 10.1002/9781119962205.ch14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
31 Canavan C, Eisenburg J, Meng L, Corey K, Hur C. Ultrasound elastography for fibrosis surveillance is cost effective in patients with chronic hepatitis C virus in the UK. Dig Dis Sci 2013;58:2691-704. [PMID: 23720196 DOI: 10.1007/s10620-013-2705-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
32 Örmeci N. Surveillance of the Patients with High Risk of Hepatocellular Cancer. J Gastrointest Cancer 2017;48:246-9. [PMID: 28634670 DOI: 10.1007/s12029-017-9972-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
33 Kuo MJ, Chen HH, Chen CL, Fann JCY, Chen SLS, Chiu SYH, Lin YM, Liao CS, Chang HC, Lin YS, Yen AMF. Cost-effectiveness analysis of population-based screening of hepatocellular carcinoma: Comparing ultrasonography with two-stage screening. World J Gastroenterol 2016; 22(12): 3460-3470 [PMID: 27022228 DOI: 10.3748/wjg.v22.i12.3460] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
34 Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98. [PMID: 26563120 DOI: 10.1007/s12072-015-9675-4] [Cited by in Crossref: 1076] [Cited by in F6Publishing: 1014] [Article Influence: 153.7] [Reference Citation Analysis]
35 Sumida Y, Yoneda M, Seko Y, Ishiba H, Hara T, Toyoda H, Yasuda S, Kumada T, Hayashi H, Kobayashi T, Imajo K, Yoneda M, Tada T, Kawaguchi T, Eguchi Y, Oeda S, Takahashi H, Tomita E, Okanoue T, Nakajima A, Japan Study Group Of Nafld Jsg-Nafld. Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Diagnostics (Basel) 2020;10:E579. [PMID: 32785100 DOI: 10.3390/diagnostics10080579] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
36 Cucchetti A, Cescon M, Erroi V, Pinna AD. Cost-effectiveness of liver cancer screening. Best Pract Res Clin Gastroenterol. 2013;27:961-972. [PMID: 24182614 DOI: 10.1016/j.bpg.2013.08.021] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
37 Lang K, Danchenko N, Gondek K, Shah S, Thompson D. The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol. 2009;50:89-99. [PMID: 18977551 DOI: 10.1016/j.jhep.2008.07.029] [Cited by in Crossref: 89] [Cited by in F6Publishing: 85] [Article Influence: 6.4] [Reference Citation Analysis]
38 Cadier B, Bulsei J, Nahon P, Seror O, Laurent A, Rosa I, Layese R, Costentin C, Cagnot C, Durand-zaleski I, Chevreul K; the ANRS CO12 CirVir and CHANGH groups. Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States: Cadier et al. Hepatology 2017;65:1237-48. [DOI: 10.1002/hep.28961] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 11.4] [Reference Citation Analysis]
39 Kim WR. The use of decision analytic models to inform clinical decision making in the management of hepatocellular carcinoma. Clin Liver Dis 2005;9:225-34. [PMID: 15831270 DOI: 10.1016/j.cld.2004.12.004] [Reference Citation Analysis]
40 Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723-750. [PMID: 29624699 DOI: 10.1002/hep.29913] [Cited by in Crossref: 1126] [Cited by in F6Publishing: 1057] [Article Influence: 375.3] [Reference Citation Analysis]
41 Sherman M. Surveillance for hepatocellular carcinoma and early diagnosis. Clin Liver Dis. 2007;11:817-837, viii. [PMID: 17981230 DOI: 10.1016/j.cld.2007.08.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
42 Wong G, Chapman JR, Craig JC. Cancer screening in renal transplant recipients: what is the evidence? Clin J Am Soc Nephrol 2008;3 Suppl 2:S87-S100. [PMID: 18309007 DOI: 10.2215/CJN.03320807] [Cited by in Crossref: 77] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
43 Balogh J, Victor D 3rd, Asham EH, Burroughs SG, Boktour M, Saharia A, Li X, Ghobrial RM, Monsour HP Jr. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:41-53. [PMID: 27785449 DOI: 10.2147/jhc.s61146] [Cited by in Crossref: 418] [Cited by in F6Publishing: 256] [Article Influence: 69.7] [Reference Citation Analysis]
44 Meer SV, Man RA, Siersema PD, Erpecum KJV. Surveillance for hepatocellular carcinoma in chronic liver disease: Evidence and controversies. World J Gastroenterol 2013; 19(40): 6744-6756 [PMID: 24187450 DOI: 10.3748/wjg.v19.i40.6744] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
45 Kumar A, Acharya SK, Singh SP, Saraswat VA, Arora A, Duseja A, Goenka MK, Jain D, Kar P, Kumar M, Kumaran V, Mohandas KM, Panda D, Paul SB, Ramachandran J, Ramesh H, Rao PN, Shah SR, Sharma H, Thandassery RB; (The INASL Task-Force on Hepatocellular Carcinoma). The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations. J Clin Exp Hepatol 2014;4:S3-S26. [PMID: 25755608 DOI: 10.1016/j.jceh.2014.04.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
46 Albrecht T. HCC-Screening. Radiologe 2008;48:33-8. [DOI: 10.1007/s00117-007-1590-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
47 Bremner KE, Bayoumi AM, Sherman M, Krahn MD. Management of solitary 1 cm to 2 cm liver nodules in patients with compensated cirrhosis: a decision analysis. Can J Gastroenterol 2007;21:491-500. [PMID: 17703248 DOI: 10.1155/2007/182383] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
48 Shankaraiah RC, Gramantieri L, Fornari F, Sabbioni S, Callegari E, Negrini M. Animal Models of Hepatocellular Carcinoma Prevention. Cancers (Basel) 2019;11:E1792. [PMID: 31739536 DOI: 10.3390/cancers11111792] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
49 Ramachandran J. Surveillance for hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4:S50-S56. [PMID: 25755611 DOI: 10.1016/j.jceh.2014.03.050] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
50 Kuang XJ, Jia RR, Huo RR, Yu JJ, Wang JJ, Xiang BD, Li LQ, Peng Z, Zhong JH. Systematic review of risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. J Viral Hepat 2018;25:1026-37. [PMID: 29624821 DOI: 10.1111/jvh.12905] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
51 Sherman M. Surveillance for hepatocellular carcinoma. Best Practice & Research Clinical Gastroenterology 2014;28:783-93. [DOI: 10.1016/j.bpg.2014.08.008] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
52 Nouso K, Tanaka H, Uematsu S, Shiraga K, Okamoto R, Onishi H, Nakamura S, Kobayashi Y, Araki Y, Aoki N. Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances. J Gastroenterol Hepatol. 2008;23:437-444. [PMID: 17683496 DOI: 10.1111/j.1440-1746.2007.05054.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
53 Nguyen ALT, Nguyen HTT, Yee KC, Palmer AJ, Blizzard CL, de Graaff B. A Systematic Review and Narrative Synthesis of Health Economic Evaluations of Hepatocellular Carcinoma Screening Strategies. Value Health 2021;24:733-43. [PMID: 33933243 DOI: 10.1016/j.jval.2020.11.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
54 Bruix J, Sherman M;  Practice Guidelines Committee;  American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236. [PMID: 16250051 DOI: 10.1002/hep.20933] [Cited by in Crossref: 4104] [Cited by in F6Publishing: 3893] [Article Influence: 241.4] [Reference Citation Analysis]
55 Reig M, Forner A, Ávila MA, Ayuso C, Mínguez B, Varela M, Bilbao I, Bilbao JI, Burrel M, Bustamante J, Ferrer J, Gómez MÁ, Llovet JM, De la Mata M, Matilla A, Pardo F, Pastrana MA, Rodríguez-Perálvarez M, Tabernero J, Urbano J, Vera R, Sangro B, Bruix J. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. Med Clin (Barc) 2021;156:463.e1-463.e30. [PMID: 33461840 DOI: 10.1016/j.medcli.2020.09.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
56 Al-Naamani K, Al-Hashami Z, Al-Siyabi O, Al-Moundri M, Al-Bahrani B, Al-Sinani S, Al-Zakwani I, Omar H, Al-Busafi SA, Al-Zuhaibi H, AlMamari A, Kamath BR, Al-Kalbani A, Burney IA. Hepatocellular Carcinoma in Oman: An analysis of 284 cases. Sultan Qaboos Univ Med J 2020;20:e316-22. [PMID: 33110647 DOI: 10.18295/squmj.2020.20.03.011] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
57 Han S, Choi JI, Park MY, Choi MH, Rha SE, Lee YJ. The Diagnostic Performance of Liver MRI without Intravenous Contrast for Detecting Hepatocellular Carcinoma: A Case-Controlled Feasibility Study. Korean J Radiol 2018;19:568-77. [PMID: 29962863 DOI: 10.3348/kjr.2018.19.4.568] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
58 Kim SH, Kim YJ, Lee JM, Choi KD, Chung YJ, Han JK, Lee JY, Lee MW, Han CJ, Choi JI, Shin KS, Choi BI. Esophageal varices in patients with cirrhosis: multidetector CT esophagography--comparison with endoscopy. Radiology. 2007;242:759-768. [PMID: 17229872 DOI: 10.1148/radiol.2423050784] [Cited by in Crossref: 70] [Cited by in F6Publishing: 54] [Article Influence: 4.7] [Reference Citation Analysis]
59 Azzaroli F, Colecchia A, Lodato F, Trerè D, Bacchi Reggiani ML, Festi D, Prati GM, Accogli E, Casanova S, Derenzini M. A statistical model predicting high hepatocyte proliferation index and the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Aliment Pharmacol Ther. 2006;24:129-136. [PMID: 16803611 DOI: 10.1111/j.1365-2036.2006.02955.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
60 Trivedi PJ, Cullen S. Autoimmune hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). Dig Dis Sci 2011;56:276-8. [PMID: 21127980 DOI: 10.1007/s10620-010-1476-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
61 Na SK, Song BC. Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C. Clin Mol Hepatol 2019;25:234-44. [PMID: 30661334 DOI: 10.3350/cmh.2018.0108] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
62 Singal AG, Marrero JA, Yopp A. Screening process failures for hepatocellular carcinoma. J Natl Compr Canc Netw 2014;12:375-82. [PMID: 24616543 DOI: 10.6004/jnccn.2014.0039] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
63 Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. Med Clin (Barc) 2016;146:511.e1-511.e22. [PMID: 26971984 DOI: 10.1016/j.medcli.2016.01.028] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
64 Kim DH, Choi JI. Current status of image-based surveillance in hepatocellular carcinoma. Ultrasonography 2021;40:45-56. [PMID: 33045812 DOI: 10.14366/usg.20067] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
65 Kim HS, El-Serag HB. The Epidemiology of Hepatocellular Carcinoma in the USA. Curr Gastroenterol Rep. 2019;21:17. [PMID: 30976932 DOI: 10.1007/s11894-019-0681-x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 12.3] [Reference Citation Analysis]
66 Della Corte C, Colombo M. Surveillance for hepatocellular carcinoma. Semin Oncol. 2012;39:384-398. [PMID: 22846857 DOI: 10.1053/j.seminoncol.2012.05.002] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 3.9] [Reference Citation Analysis]
67 Francica G, Borzio M. Status of, and strategies for improving, adherence to HCC screening and surveillance. J Hepatocell Carcinoma 2019;6:131-41. [PMID: 31440486 DOI: 10.2147/JHC.S159269] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
68 Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases: Marrero et al. Hepatology 2018;68:723-50. [DOI: 10.1002/hep.29913] [78495111110.1002/hep.29913','', '1948-5182')">Reference Citation Analysis]
69 El-Serag HB, Davila JA. Surveillance for hepatocellular carcinoma: in whom and how? Therap Adv Gastroenterol. 2011;4:5-10. [PMID: 21317990 DOI: 10.1177/1756283x10385964] [Cited by in Crossref: 77] [Cited by in F6Publishing: 43] [Article Influence: 7.0] [Reference Citation Analysis]
70 Kim H, Choi D, Gwak GY, Lee JH, Park MK, Lee HIe, Kim SH, Nam S, Yoo EY, Do YS. Evaluation of esophageal varices on liver computed tomography: receiver operating characteristic analyses of the performance of radiologists and endoscopists. J Gastroenterol Hepatol. 2009;24:1534-1540. [PMID: 19486446 DOI: 10.1111/j.1440-1746.2009.05849.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
71 Anugwom CM, Allaire M, Akbar SMF, Sultan A, Bollipo S, Mattos AZ, Debes JD. Hepatitis B-related hepatocellular carcinoma: surveillance strategy directed by immune-epidemiology. Hepatoma Res 2021;7:23. [PMID: 33884303 DOI: 10.20517/2394-5079.2021.06] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
72 Tanaka H, Iijima H, Nouso K, Aoki N, Iwai T, Takashima T, Sakai Y, Aizawa N, Iwata K, Ikeda N, Iwata Y, Enomoto H, Saito M, Imanishi H, Nishiguchi S. Cost-effectiveness analysis on the surveillance for hepatocellular carcinoma in liver cirrhosis patients using contrast-enhanced ultrasonography: Cost-effectiveness of CEUS surveillance for HCC. Hepatology Research 2012;42:376-84. [DOI: 10.1111/j.1872-034x.2011.00936.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
73 Danta M, Barnes E, Dusheiko G. The surveillance and diagnosis of hepatocellular carcinoma: . European Journal of Gastroenterology & Hepatology 2005;17:491-6. [DOI: 10.1097/00042737-200505000-00004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
74 Likhitsup A, Parikh ND. Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians. Pharmacoeconomics 2020;38:5-24. [PMID: 31573053 DOI: 10.1007/s40273-019-00839-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
75 Natarajan Y, Tansel A, Patel P, Emologu K, Shukla R, Qureshi Z, El-Serag HB, Thrift AP, Kanwal F. Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. Dig Dis Sci 2021;66:2439-51. [PMID: 32743773 DOI: 10.1007/s10620-020-06498-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
76 Lim TH, Gane E, Moyes C, Borman B, Cunningham C. HBsAg loss in a New Zealand community study with 28-year follow-up: rates, predictors and long-term outcomes. Hepatol Int. 2016;10:829-837. [PMID: 26957439 DOI: 10.1007/s12072-016-9709-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
77 Stotts MJ, Grischkan JA, Khungar V. Improving cirrhosis care: The potential for telemedicine and mobile health technologies. World J Gastroenterol 2019; 25(29): 3849-3856 [PMID: 31413523 DOI: 10.3748/wjg.v25.i29.3849] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
78 Amarapurkar D, Han K, Chan HL, Ueno Y; The Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma. Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region. Journal of Gastroenterology and Hepatology 2009;24:955-61. [DOI: 10.1111/j.1440-1746.2009.05805.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 3.9] [Reference Citation Analysis]
79 Sherman M. Primary Malignant Neoplasms of the Liver. In: Dooley JS, Lok ASF, Burroughs AK, Heathcote EJ, editors. Sherlock's Diseases of the Liver and Biliary System. Oxford: Wiley-Blackwell; 2011. pp. 681-703. [DOI: 10.1002/9781444341294.ch35] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
80 Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Jackson S, Ryder S, Cramp M, Stein K. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. Br J Cancer. 2008;98:1166-1175. [PMID: 18382459 DOI: 10.1038/sj.bjc.6604301] [Cited by in Crossref: 74] [Cited by in F6Publishing: 72] [Article Influence: 5.3] [Reference Citation Analysis]
81 Del Poggio P, Mazzoleni M, Lazzaroni S, D'Alessio A. Surveillance for hepatocellular carcinoma at the community level: Easier said than done. World J Gastroenterol 2021; 27(37): 6180-6190 [PMID: 34712026 DOI: 10.3748/wjg.v27.i37.6180] [Reference Citation Analysis]
82 Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. [PMID: 27158749 DOI: 10.1038/nrdp.2016.18] [Cited by in Crossref: 941] [Cited by in F6Publishing: 982] [Article Influence: 156.8] [Reference Citation Analysis]
83 Iavarone M, Colombo M. HBV-related HCC, clinical issues and therapy. Dig Liver Dis. 2011;43 Suppl 1:S32-S39. [PMID: 21195370 DOI: 10.1016/S1590-8658(10)60690-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
84 Saab S, Alper T, Sernas E, Pruthi P, Alper MA, Sundaram V. Hospitalized Patients with Cirrhosis Should Be Screened for Clostridium difficile Colitis. Dig Dis Sci 2015;60:3124-9. [DOI: 10.1007/s10620-015-3707-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
85 Otgonsuren M, Henry L, Hunt S, Venkatesan C, Mishra A, Younossi ZM. Resource Utilization and Survival Among Medicare Patients with Advanced Liver Disease. Dig Dis Sci 2015;60:320-32. [DOI: 10.1007/s10620-014-3318-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
86 Andersson KL, Salomon JA, Goldie SJ, Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2008;6:1418-1424. [PMID: 18848905 DOI: 10.1016/j.cgh.2008.08.005] [Cited by in Crossref: 139] [Cited by in F6Publishing: 118] [Article Influence: 9.9] [Reference Citation Analysis]
87 Harris PS, Hansen RM, Gray ME, Massoud OI, McGuire BM, Shoreibah MG. Hepatocellular carcinoma surveillance: An evidence-based approach. World J Gastroenterol 2019; 25(13): 1550-1559 [PMID: 30983815 DOI: 10.3748/wjg.v25.i13.1550] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 38] [Article Influence: 14.7] [Reference Citation Analysis]
88 Vilana R, Forner A, García Á, Ayuso C, Bru C. Carcinoma hepatocelular: diagnóstico, estadificación y estrategia terapéutica. Radiología 2010;52:385-98. [DOI: 10.1016/j.rx.2010.05.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
89 Sherman M. Chronic hepatitis C and screening for hepatocellular carcinoma. Clin Liver Dis. 2006;10:735-752. [PMID: 17164115 DOI: 10.1016/j.cld.2006.08.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
90 Ioannou GN, Splan MF, Weiss NS, McDonald GB, Beretta L, Lee SP. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2007; 5: 938-945, 945.e1-945. e4. [PMID: 17509946 DOI: 10.1016/j.cgh.2007.02.039] [Cited by in Crossref: 140] [Cited by in F6Publishing: 127] [Article Influence: 9.3] [Reference Citation Analysis]
91 Patel D, Terrault NA, Yao FY, Bass NM, Ladabaum U. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2005;3:75-84. [PMID: 15645408 DOI: 10.1016/s1542-3565(04)00443-4] [Cited by in Crossref: 65] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
92 Tansel A, Katz LH, El-Serag HB, Thrift AP, Parepally M, Shakhatreh MH, Kanwal F. Incidence and Determinants of Hepatocellular Carcinoma in Autoimmune Hepatitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2017; 15: 1207-1217. e4. [PMID: 28215616 DOI: 10.1016/j.cgh.2017.02.006] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 7.6] [Reference Citation Analysis]
93 Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317-370. [PMID: 28620797 DOI: 10.1007/s12072-017-9799-9] [Cited by in Crossref: 661] [Cited by in F6Publishing: 667] [Article Influence: 132.2] [Reference Citation Analysis]
94 Forner A, Ayuso C, Isabel Real M, Sastre J, Robles R, Sangro B, Varela M, de la Mata M, Buti M, Martí-Bonmatí L, Bru C, Tabernero J, Llovet JM, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma]. Med Clin (Barc) 2009;132:272-87. [PMID: 19248879 DOI: 10.1016/j.medcli.2008.11.024] [Cited by in Crossref: 56] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
95 Goossens N, Bian CB, Hoshida Y. Tailored algorithms for hepatocellular carcinoma surveillance: Is one-size-fits-all strategy outdated? Curr Hepatol Rep 2017;16:64-71. [PMID: 28337405 DOI: 10.1007/s11901-017-0336-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
96 Marrero JA. Hepatocellular carcinoma: . Current Opinion in Gastroenterology 2005;21:308-12. [DOI: 10.1097/01.mog.0000159817.55661.ca] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
97 Wan DW, Tzimas D, Smith JA, Kim S, Araujo J, David R, Lobach I, Sarpel U. Risk factors for early-onset and late-onset hepatocellular carcinoma in Asian immigrants with hepatitis B in the United States. Am J Gastroenterol. 2011;106:1994-2000. [PMID: 21912436 DOI: 10.1038/ajg.2011.302] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
98 Colombo M. Screening. Hepatology Research 2007;37:S146-51. [DOI: 10.1111/j.1872-034x.2007.00179.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
99 Sherman M, Bruix J, Porayko M, Tran T; AASLD Practice Guidelines Committee. Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases recommendations. Hepatology. 2012;56:793-796. [PMID: 22689409 DOI: 10.1002/hep.25869] [Cited by in Crossref: 104] [Cited by in F6Publishing: 98] [Article Influence: 10.4] [Reference Citation Analysis]
100 Simpson HN, McGuire BM. Screening and detection of hepatocellular carcinoma. Clin Liver Dis 2015;19:295-307. [PMID: 25921664 DOI: 10.1016/j.cld.2015.01.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
101 Marrero JA. Surveillance for Hepatocellular Carcinoma. Clin Liver Dis 2020;24:611-21. [PMID: 33012448 DOI: 10.1016/j.cld.2020.07.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
102 Llovet JM, Zucman-rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma. Nat Rev Dis Primers 2016;2. [DOI: 10.1038/nrdp.2016.18] [78495111110.1038/nrdp.2016.18','', '1948-5182')">Reference Citation Analysis]